CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
✉ Email this page to a colleague
All Clinical Trials for amino acids; magnesium acetate; potassium acetate; sodium chloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00212043 ↗ | Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma | Completed | Eli Lilly and Company | Phase 2 | 2000-07-01 | Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer |
NCT00212043 ↗ | Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma | Completed | National University Hospital, Singapore | Phase 2 | 2000-07-01 | Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer |
NCT02294656 ↗ | Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide | Completed | Genentech, Inc. | Phase 1 | 2014-11-01 | This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amino acids; magnesium acetate; potassium acetate; sodium chloride
Condition Name
Clinical Trial Locations for amino acids; magnesium acetate; potassium acetate; sodium chloride
Trials by Country
Clinical Trial Progress for amino acids; magnesium acetate; potassium acetate; sodium chloride
Clinical Trial Phase
Clinical Trial Sponsors for amino acids; magnesium acetate; potassium acetate; sodium chloride
Sponsor Name
Sponsor Name for amino acids; magnesium acetate; potassium acetate; sodium chloride | |
Sponsor | Trials |
Haining Health-Coming Biotech Co., Ltd. | 1 |
Eli Lilly and Company | 1 |
National University Hospital, Singapore | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |